Gavin Clark-Gartner
Stock Analyst at Evercore ISI Group
(2.17)
# 2,879
Out of 5,005 analysts
34
Total ratings
50%
Success rate
-4.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gavin Clark-Gartner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | Maintains: Outperform | $20 → $14 | $2.49 | +462.25% | 4 | Sep 22, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $207 → $222 | $233.91 | -5.09% | 5 | Sep 22, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $77 → $89 | $72.95 | +22.00% | 3 | Aug 8, 2025 | |
| PRQR ProQR Therapeutics | Initiates: Outperform | $5 | $2.45 | +104.08% | 1 | Apr 29, 2025 | |
| MNMD Mind Medicine (MindMed) | Initiates: Outperform | $23 | $12.56 | +83.12% | 1 | Jan 28, 2025 | |
| CABA Cabaletta Bio | Downgrades: In-Line | $15 → $6 | $2.44 | +145.90% | 2 | Dec 20, 2024 | |
| ARGX argenx SE | Maintains: Outperform | $675 → $706 | $800.00 | -11.75% | 4 | Nov 21, 2024 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $179 → $170 | $22.64 | +650.88% | 9 | Nov 7, 2024 | |
| FHTX Foghorn Therapeutics | Initiates: Outperform | $20 | $4.64 | +331.03% | 1 | Aug 19, 2024 | |
| KRYS Krystal Biotech | Maintains: Outperform | $201 → $206 | $183.36 | +12.35% | 1 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $1.86 | +1,082.80% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $10 | $2.27 | +340.53% | 1 | May 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $60 | $35.65 | +68.30% | 1 | Oct 5, 2022 |
Jasper Therapeutics
Sep 22, 2025
Maintains: Outperform
Price Target: $20 → $14
Current: $2.49
Upside: +462.25%
AbbVie
Sep 22, 2025
Maintains: Outperform
Price Target: $207 → $222
Current: $233.91
Upside: -5.09%
Mirum Pharmaceuticals
Aug 8, 2025
Maintains: Outperform
Price Target: $77 → $89
Current: $72.95
Upside: +22.00%
ProQR Therapeutics
Apr 29, 2025
Initiates: Outperform
Price Target: $5
Current: $2.45
Upside: +104.08%
Mind Medicine (MindMed)
Jan 28, 2025
Initiates: Outperform
Price Target: $23
Current: $12.56
Upside: +83.12%
Cabaletta Bio
Dec 20, 2024
Downgrades: In-Line
Price Target: $15 → $6
Current: $2.44
Upside: +145.90%
argenx SE
Nov 21, 2024
Maintains: Outperform
Price Target: $675 → $706
Current: $800.00
Upside: -11.75%
Sarepta Therapeutics
Nov 7, 2024
Maintains: Outperform
Price Target: $179 → $170
Current: $22.64
Upside: +650.88%
Foghorn Therapeutics
Aug 19, 2024
Initiates: Outperform
Price Target: $20
Current: $4.64
Upside: +331.03%
Krystal Biotech
Aug 12, 2024
Maintains: Outperform
Price Target: $201 → $206
Current: $183.36
Upside: +12.35%
Oct 3, 2023
Initiates: Outperform
Price Target: $22
Current: $1.86
Upside: +1,082.80%
May 30, 2023
Maintains: Outperform
Price Target: $20 → $10
Current: $2.27
Upside: +340.53%
Oct 5, 2022
Maintains: Outperform
Price Target: $54 → $60
Current: $35.65
Upside: +68.30%